文献速递妇科

机构层面新辅助化疗使用率的差异与晚期上皮性卵巢癌患者更高的手术并发症相关

Facility level variation in the utilization of neoadjuvant chemotherapy is associated with higher surgical morbidity for patients with advanced stage epithelial ovarian carcinoma.
PubMed 文献 · Gynecol Oncol · 2022-12-08

研究利用美国国家癌症数据库2010至2016年诊断的III-IV期上皮性卵巢癌患者,按机构新辅助化疗使用率高低分组,比较手术结局与生存。高使用率机构治疗的患者分期更晚、合并症更多,但原发肿瘤减灭术后的完全肉眼切除率更高、90天死亡率和30天非计划再入院率更低,总生存无显著差异。

要点

  • 高使用率机构平均对54.1%的患者使用新辅助化疗,低使用率机构为25.4%。
  • 低使用率机构接受原发肿瘤减灭术的患者完全肉眼切除率显著更低,90天死亡率和30天非计划再入院率显著更高。
  • 调整后高使用率机构总生存有改善趋势(HR 0.92,95%CI 0.85-0.99)。

核心结论

  • 高使用率机构尽管治疗的患者疾病更晚期且合并症更多,但手术并发症和死亡率更低,且对长期生存无不利影响。
  • 作者认为仔细选择患者以尽量减少原发肿瘤减灭术相关并发症和死亡率至关重要。

研究设计与样本

  • 研究为基于美国国家癌症数据库的队列分析,纳入2010至2016年诊断的III-IV期上皮性卵巢癌患者。
  • 计算报告至少120例患者的机构的新辅助化疗使用率,使用率最低和最高四分位数的机构分别构成低使用率组和高使用率组。

主要发现

  • 高使用率机构平均对54.1%的患者使用新辅助化疗,低使用率机构平均为25.4%。
  • 高使用率机构治疗的患者更可能年龄>65岁(p=0.029)、为IV期(p<0.001)和有合并症(p<0.001)。
  • 低使用率机构接受原发肿瘤减灭术的患者完全肉眼切除率显著更低(p<0.001),90天死亡率(p<0.001)和30天非计划再入院率(p<0.001)显著更高。
  • 调整年龄、合并症、种族、保险状态、分期、分级和组织学后,高使用率机构总生存有改善趋势(HR 0.92,95%CI 0.85-0.99)。
  • 总体而言,接受原发肿瘤减灭术的患者总生存优于接受新辅助化疗者(中位42个月 vs 27个月,p<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Investigate outcomes for advanced stage epithelial ovarian cancer (EOC) patients based on facility-level utilization of neoadjuvant chemotherapy (NACT). METHODS: Stage III-IV EOC patients diagnosed between 2010 and 2016 were identified in the National Cancer Database. Percentage of patients managed with NACT was calculated for facilities, reporting ≥120 patients. Facilities with lowest and highest quartile of NACT rate comprised the low and high-utilizing groups. Clinico-pathological characteristics were collected, and appropriate statistical analysis performed. RESULTS: High- and low-utilizing facilities managed on average 54.1% and 25.4% of patients with NACT respectively. Patients managed at high-utilizing facilities were significantly more likely to be >65 (p = 0.029), have stage IV disease (p < 0.001) and comorbidities (p < 0.001). Patients managed with primary debulking surgery (PDS) at low-utilizing facilities were significantly more likely to be >65, have stage IV disease, and have comorbidities (all, p < 0.001). Patients undergoing PDS at low-utilizing facilities were significantly less likely to achieve complete gross resection (p < 0.001), and were significantly more likely to experience 90-day mortality (p < 0.001), and unplanned 30-day readmission (p < 0.001). After controlling for age, comorbidities, race, insurance status, stage, grade and histology, high-utilizing facilities trended towards better overall survival (OS) (HR: 0.92, 95% CI: 0.85-0.99). Overall, patients undergoing PDS had better OS compared to those who had NACT (median 42 vs 27 months, p < 0.001). CONCLUSIONS: Despite treating an EOC population with more advanced disease and comorbidities, high-utilizing facilities have lower surgical morbidity and mortality with no detrimental impact on long-term survival. Careful patient selection to minimize the morbidity and mortality associated with PDS is pivotal.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Nasioudis D, Latif NA, Ko EM, et al. Facility level variation in the utilization of neoadjuvant chemotherapy is associated with higher surgical morbidity for patients with advanced stage epithelial ovarian carcinoma. Gynecol Oncol. 2022. PMID: 36502768. doi:10.1016/j.ygyno.2022.10.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。